212 related articles for article (PubMed ID: 29689546)
41. Silencing of tachyzoite enolase 2 alters nuclear targeting of bradyzoite enolase 1 in Toxoplasma gondii.
Holmes M; Liwak U; Pricop I; Wang X; Tomavo S; Ananvoranich S
Microbes Infect; 2010 Jan; 12(1):19-27. PubMed ID: 19770069
[TBL] [Abstract][Full Text] [Related]
42. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.
Bachmann PS; Gorman R; Papa RA; Bardell JE; Ford J; Kees UR; Marshall GM; Lock RB
Cancer Res; 2007 May; 67(9):4482-90. PubMed ID: 17483364
[TBL] [Abstract][Full Text] [Related]
43. [Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia].
Xu B; Wang BJ; Li AM; Lock R
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):151-4. PubMed ID: 16613713
[TBL] [Abstract][Full Text] [Related]
44. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.
Wu Y; Sarkissyan M; Mcghee E; Lee S; Vadgama JV
Breast Cancer Res Treat; 2015 Jun; 151(3):529-39. PubMed ID: 25975952
[TBL] [Abstract][Full Text] [Related]
45. Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.
Sheard MA; Ghent MV; Cabral DJ; Lee JC; Khankaldyyan V; Ji L; Wu SQ; Kang MH; Sposto R; Asgharzadeh S; Reynolds CP
Exp Cell Res; 2015 May; 334(1):78-89. PubMed ID: 25845499
[TBL] [Abstract][Full Text] [Related]
46. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
47. Expression differences in TEL-AML1 fusion gene in leukemia glucocorticoid-sensitive and -resistant cell lines.
Wang XW; Xu YH
Genet Mol Res; 2015 Jul; 14(3):7883-93. PubMed ID: 26214469
[TBL] [Abstract][Full Text] [Related]
48. FGF18 Enhances Migration and the Epithelial-Mesenchymal Transition in Breast Cancer by Regulating Akt/GSK3β/Β-Catenin Signaling.
Song N; Zhong J; Hu Q; Gu T; Yang B; Zhang J; Yu J; Ma X; Chen Q; Qi J; Liu Y; Su W; Feng Z; Wang X; Wang H
Cell Physiol Biochem; 2018; 49(3):1019-1032. PubMed ID: 30196303
[TBL] [Abstract][Full Text] [Related]
49. Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells.
Gu L; Findley HW; Zhu N; Zhou M
Leukemia; 2006 May; 20(5):900-4. PubMed ID: 16511511
[No Abstract] [Full Text] [Related]
50. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
[TBL] [Abstract][Full Text] [Related]
51. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
52. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
53. ENO2 activity is required for the development and reproductive success of plants, and is feedback-repressed by AtMBP-1.
Eremina M; Rozhon W; Yang S; Poppenberger B
Plant J; 2015 Mar; 81(6):895-906. PubMed ID: 25620024
[TBL] [Abstract][Full Text] [Related]
54. Knockdown of Slit2 promotes growth and motility in gastric cancer cells via activation of AKT/β-catenin.
Shi R; Yang Z; Liu W; Liu B; Xu Z; Zhang Z
Oncol Rep; 2014 Feb; 31(2):812-8. PubMed ID: 24297051
[TBL] [Abstract][Full Text] [Related]
55. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
56. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
[TBL] [Abstract][Full Text] [Related]
57. PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia.
Hui PY; Chen YH; Qin J; Jiang XH
Hematology; 2022 Dec; 27(1):32-42. PubMed ID: 34957927
[TBL] [Abstract][Full Text] [Related]
58. TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Zhao Q; Zhao S; Li J; Zhang H; Qian C; Wang H; Liu J; Zhao Y
Biomed Pharmacother; 2019 Jan; 109():1640-1649. PubMed ID: 30551418
[TBL] [Abstract][Full Text] [Related]
59. Krüppel-like factor 12 suppresses bladder cancer growth through transcriptionally inhibition of enolase 2.
Tang C; Wang M; Dai Y; Wei X
Gene; 2021 Feb; 769():145338. PubMed ID: 33279628
[TBL] [Abstract][Full Text] [Related]
60. The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells.
Chen T; Meng Z; Gan Y; Wang X; Xu F; Gu Y; Xu X; Tang J; Zhou H; Zhang X; Gan X; Van Ness C; Xu G; Huang L; Zhang X; Fang Y; Wu J; Zheng S; Jin J; Huang W; Xu R
Leukemia; 2013 Jul; 27(7):1469-78. PubMed ID: 23307033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
